Key Takeaways

  • Researchers at Calico and Revel Pharma used Google's AlphaFold AI to discover a novel enzyme capable of degrading CML, a major advanced glycation end product (AGE) that accumulates in the extracellular matrix and drives aging.
  • This AI-driven enzyme successfully eliminated between 52-97% of CML in various proteins, demonstrating its effectiveness in breaking down these stubborn age-accelerants.
  • When applied to elderly human skin samples (from patients over 70), the enzyme reduced CML by 55%, effectively reversing the skin's biological age to that of a 31-year-old.
  • The initial market for this enzyme is expected to be the multi-trillion dollar cosmetic industry, with topical creams offering age-reversing benefits a likely first application.

The Unseen Enemy of Aging

Forget your cells for a moment. What's happening outside them? That's where a lot of aging takes root, in what scientists call the extracellular matrix. David Friedberg explained the mechanism, saying, “What they focused on was what's called the extracellular matrix. The parts outside of the cell that age.” Over time, sugars and fats bind to proteins in this space, forming nasty compounds that build up and stiffen tissues. Think wrinkles, reduced mobility, and the general stiffening that comes with age.

One of the main culprits in this process is a molecule called CML, or advanced glycation end product. Friedberg made it clear: “CML is kind of the predominant molecule that that gets formed in this extracellular matrix that's driving aging and nothing breaks it down.” For decades, CML has been a known accelerator of aging, yet no natural process or drug could effectively dismantle it. This wasn't just a tough problem; it was an "undruggable" one, leaving a massive gap in anti-aging science.

AI's Breakthrough in Biology

Enter artificial intelligence. Specifically, Google's AlphaFold, a tool that predicts protein structures with startling accuracy. Friedberg detailed how this powerful AI was deployed: “They started with AlphaFold and they used Alphafold to find a protein that could bind to CML and activate an enzyatic or process that would break it down.” This wasn't a shot in the dark; it was directed evolution, using AI to fast-track the discovery of an enzyme perfectly tailored to a previously intractable problem.

The research, a collaboration between Calico and Revel Pharma, shows the sheer force of AI when applied to complex biological challenges. Traditional drug discovery takes years, sometimes decades, and often ends in failure. AlphaFold slashed through that complexity, identifying a novel enzyme that didn't just bind to CML, but actively broke it down, offering a solution to a problem that seemed insurmountable.

Turning Back the Clock, Literally

The results were more than impressive; they were astonishing. The newly discovered enzyme didn't just degrade CML in a petri dish. It worked wonders on human tissue. In lab tests, it eradicated between 52% and 97% of CML from various proteins. But the real headline came from human skin samples. Friedberg confirmed that by applying this enzyme to skin from patients over 70, “they were able to eliminate 55% of the CML on the skin which basically reversed the skin's age down to the age of a 31y old.”

Imagine that: a topical application reversing decades of visible aging. Jason Calacanis, one of the podcast hosts, immediately grasped the market implications, stating, “If if you can create a cream, dude, if you could put this enzyme literally on your skin and have it absorb, Game over. It's it's a that that alone is $2 trillion.” This isn't just about reducing wrinkles; it's about fundamentally resetting the biological clock of our largest organ, opening the door to a multi-trillion dollar industry just for cosmetics, with broader health applications likely to follow.

What to Do With This

For ambitious founders, this isn't just a science update; it's a blueprint for disruption. First, rethink "undruggable" or "unsolvable" problems in your industry. AI tools like AlphaFold are collapsing the time and cost of solving previously intractable scientific challenges. Second, scan established, multi-trillion dollar markets (think health, food, energy, manufacturing) for fundamental, age-old problems that have been left untouched. This enzyme is proving that AI can unlock entirely new solutions to these entrenched issues, creating massive greenfield opportunities.